Metraipolis › archive › dc_ca5594b89ed0
Barriers and facilitators to hepatitis B birth dose vaccination: Perspectives from healthcare providers and pregnant women accessing antenatal care in Nigeria — Europe PMC PMID:37289735
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/37289735
- DOI
- 10.1371/journal.pgph.0001332
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-07T12:59:28.283Z
- SHA-256 of the archived text
8aad2dcd102bab1fe97c5c39555e22ed4a7868ff92f1bfe166d38ec9a196f79c- Stable URL of this page
https://metraipolis.com/documento/dc_ca5594b89ed0
How to cite
Barriers and facilitators to hepatitis B birth dose vaccination: Perspectives from healthcare providers and pregnant women accessing antenatal care in Nigeria — Europe PMC PMID:37289735 — Europe PMC (en), https://europepmc.org/article/MED/37289735 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_ca5594b89ed0 (Metraipolis archive dc_ca5594b89ed0, sha256 8aad2dcd102bab1fe97c5c39555e22ed4a7868ff92f1bfe166d38ec9a196f79c)
BibTeX
@misc{dcca5594b89ed0,
title = {Barriers and facilitators to hepatitis B birth dose vaccination: Perspectives from healthcare providers and pregnant women accessing antenatal care in Nigeria — Europe PMC PMID:37289735},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/37289735},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_ca5594b89ed0; sha256 8aad2dcd102bab1fe97c5c39555e22ed4a7868ff92f1bfe166d38ec9a196f79c},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/37289735. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Nigeria is estimated to have the largest number of children worldwide, living with chronic hepatitis B virus (HBV) infection, the leading cause of liver cancer. Up to 90% of children infected at birth develop chronic HBV infection. A birth dose of the hepatitis B vaccine (HepB-BD) followed by at least two additional vaccine doses is recommended for prevention. This study assessed barriers and facilitators of HepB-BD administration and uptake, using structured interviews with healthcare providers and pregnant women in Adamawa and Enugu States, Nigeria. The Consolidated Framework for Implementation Sciences Research (CFIR) guided data collection and analysis. We interviewed 87 key informants (40 healthcare providers and 47 pregnant women) and created a codebook for data analysis. Codes were developed by reviewing the literature and reading a subsample of queries line-by-line. The overarching themes identified as barriers among healthcare providers were: the lack of hepatitis B knowledge, limited availability of HepB-BD to vaccination days only, misconceptions about HepB-BD vaccination, challenges in health facility staffing capacity, costs associated with vaccine transportation, and concerns related to vaccine wastage. Facilitators of timely HepB-BD vaccination included: vaccine availability, storage, and hospital births occurring during immunization days. Overarching themes identified as barriers among pregnant women were lack of hepatitis B knowledge, limited understanding of HepB-BD importance, and limited access to vaccines for births occurring outside of a health facility. Facilitators were high vaccine acceptance and willingness for their infants to receive HepB-BD if recommended by providers. Findings indicate the need for enhanced HepB-BD vaccination training for HCWs, educating pregnant women on HBV and the importance of timely HepB-BD, updating policies to enable HepB-BD administration within 24 hours of birth, expanding HepB-BD availability in public and private hospital maternity wards for all facility births, and outreach activities to reach home births. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PLOS global public health, 2023 (prima pubblicazione 2023-06-08). Identificativi: PMID 37289735 · PMCID PMC10249797 · DOI 10.1371/journal.pgph.0001332. Pagina: https://europepmc.org/article/MED/37289735 — https://doi.org/10.1371/journal.pgph.0001332. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-07T12:29:42.023Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.